Age (years) <50 20 (56%) 16 (33%) 0.042 ≥50 16 (44%) 32 (67%) Tumour size T1 (≤2.0 cm) 16 (44%) 17 (35%) NS T2 (>2.0 cm to ≤5.0 cm) 18 (50%) 25 (52%) T3 (>5.0 cm) 2 (6%) 6 (13%) Aluston andon

The relationship between lysophosphatidic acid receptor 2 (LPA2) expression and clinical/pathological factor

High (48)

17 (35%)

31 (65%)

27 (56%)

21 (44%)

21 (44%)

27 (56%)

41 (85%)

7 (15%)

P

0.037

NS

NS

NS

Low (36)

21 (58%)

15 (42%)

10 (55%)

8 (45%)

12 (33%)

24 (67%)

27 (75%)

9 (25%)

Numbers in parentheses indicate percentages in the same expression pattern. NS, not significant.

LPA2 expression

Menopausal status

Negative

Positive

Nodal metastasis

Negative

Positive

Negative

Positive

Distant metastasis

Premenopausal

Postmenopausal

Oestrogen receptor status

5 (10%) NS
31 (65%)
12 (25%)